|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||17.51 - 17.61|
|52 Week Range||16.15 - 33.30|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.50|
NEW YORK, March 20, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that.
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, presented new clinical results from its Study 106 program in the prevention of chemotherapy induced neutropenia (CIN) for its lead asset Plinabulin at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The data showed that, through combining Plinabulin with Neulasta, patients not only experienced better outcomes for CIN treatment, but Neulasta’s potential immune-suppressive phenotype was also reduced.
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced new clinical results from its Study 106 program for lead asset Plinabulin, which demonstrates that combining Plinabulin with Neulasta (pegfilgrastim) not only improves overall efficacy for chemotherapy-induced neutropenia (CIN) treatment but also reverses Neulasta’s potential immune-suppressive phenotype. The data will be presented by Dr. Douglas Blayney, global Principal Investigator for BeyondSpring’s CIN development program and Professor of Medicine at Stanford University Medical Center, in a poster presentation titled, “A Phase II trial with the Combination of Plinabulin and Pegfilgrastim: Evaluation of the Reversal of Peg’s Immune-Suppressive Potential by the Addition of Plin to Peg,” at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it had a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead asset, Plinabulin. The focus of this meeting was the content of the chemistry, manufacturing and control (CMC) sections of the Company’s planned NDAs for Plinabulin for the treatment of non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN) prevention.
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company U.S. Patent No. 10,155,748 related to a new composition of matter of BeyondSpring’s lead asset, Plinabulin. This composition of matter patent is directed to Plinabulin’s monohydrate in a crystalline form and provides patent protection in the U.S. until 2036. “Adding yet another vital patent to BeyondSpring’s robust global intellectual property (IP) portfolio enables us to effectively maximize Plinabulin’s commercial potential across therapeutic indications, starting with chemotherapy-induced neutropenia (CIN) prevention and non-small cell lung cancer (NSCLC) treatment, followed by combinations with immunotherapies,” said Dr. Huang.
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta® for the duration of severe neutropenia (DSN) of the first cycle, with statistical significance in a pre-specified interim analysis. In this trial, Plinabulin as a single agent was compared head-to-head with Neulasta as a single agent.
Plinabulin monotherapy is an equally effective single-dose-per cycle agent as pegfilgrastim, but with minimal bone pain vs. pegfilgrastim in intermediate neutropenic risk.
The patent covers methods for Plinabulin’s use in treating or reducing the incidence of grade 3 or 4 CIN in patients who are being treated with taxane, including instances where the taxane is docetaxel, with patent protection until 2033 in Japan. Dr. Lan Huang, BeyondSpring co-founder and CEO, is the author of this newly granted patent.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
If you want to know who really controls BeyondSpring Inc (NASDAQ:BYSI), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...